November 2009
20: But These Reagents, Where Are They?
20: Merck, Shopping in the UK?
19: What Are the Best Med-Chem Books?
19: Plavix vs. Effient
18: More For the Blogroll
18: I'll Get Right On That For You, Professor
17: Side Effects, Predicted?
17: A Blogroll Update
17: Warren DeLano
16: Zetia Takes Another Torpedo
13: Prof. Keith Fagnou
13: Lumpy Assay Results
12: Massaging the Data for Neurontin?
11: Go Spread It On the Rosebushes
11: Against Panic
11: Telling the Layoff Story
11: Pfizer's Chemistry Head Count - Really?
10: Lab Equipment: Any H-Cube Troubleshooters Out There?
10: Pfizer's Site Closures - An Analysis
09: Pfizer's New Layout
09: So, Do I Own This, Or What? Answer: What
09: Selling It, And Selling It Hard
06: Thoughts on What Used to Be Schering-Plough
05: What Exactly Does Resveratrol Do?
04: Are You Now, Or Have You Ever Been. . .?
03: J&J Raises the Ax
03: That Didn't Take Very Long
02: In Which You Get to Hear the Phrase "Hatch-Waxman" Again

October 2009
30: Fifty Years of Scientific History For You
29: The Best Ones Aren't Over Here Any More?
29: Four Med-Chem Questions
28: Nanotech Armor
28: You Mean You Don't Have to Buy Them?
27: Reduce Your Number of Reductions, Why Don't You?
26: Elements I Have Yet to Use
23: Things I Won't Work With: Straight Dimethyl Zinc
22: Red Flags in Biotech
21: "Back to School"
21: Pfizer's People
21: O Brave New World! That Has Such Companies In't!
20: What Pfizer Will Look Like in a Year
19: Short Topics From All Over
16: "Day One" at Pfizer
16: Engineering Receptors: Not Quite There Yet. Not Exactly.
15: Fall From Grace
14: Consultants
13: Those Zanies at Angewandte Chemie
13: Chronic Fatigue - Retroviruses to Blame, or Not?
12: Day Off
09: I'll See Your Conflicts, and Raise You?
08: Hoist, Petard, Etc.
08: Retire These Reactions!
07: A Nobel for Ribosome Structure
06: Traveling, Updates Later
05: A Nobel for Telomerase
02: Placebos Can Work the Other Way, Too
01: Traffic Record
01: How To Get Useful Data Out of a Drug Patent

September 2009
30: Ignoring Patents?
30: Microwaves Aren't Magic
29: Nobel Season 2009
28: Which Pfizer / Wyeth Sites Will Close?
28: Chew On This, Enzyme
25: The Details of the Baucus Bill
25: Faked Data at the ETH
24: The Grant Application Treadmill
24: Obesity: Hope Springs Eternal (Summer 2009 Version)
23: PNAS Shuts a Door
23: Pay Them Now, Or Pay For It Later
22: Statin Safety?
22: Colorful Junk
21: More on T2, and Degrees
18: 175 Times. And Then the Catastrophe.
17: The Drug Business: A Turbulent Future?
16: Real Electrons
15: Lilly Shrinks
15: Industrial Research: More Grounded in Reality, or Not?
14: Abstract Abstracts
14: Norman Borlaug
11: Antioxidants and Cancer: Backwards?
10: To What End?
09: "Scratch and Sniff" Turns Into "Zap and React"
08: Right Where You Want Them
04: Pharma Whistleblowing: How It Works
04: Sepracor: A Desirable Property?
03: Real Molecules
03: A 2.3 Billion Dollar Attention-Getter
02: Lexapro, Forest Labs, and the Hard Sell
01: Another Iron Reaction Hits The Mat
01: Back

August 2009
28: REACH for the Sky!
27: Rings of the Future!
26: Thalidomide for Myeloma: Whose Idea Was It?
26: Ariad's Patent Rises From the Grave to Smite the Living
25: Polymorphs and Salts: India Raises an Eyebrow
24: Arzoxifene: Not the Road to Big Profits?
21: Obesity Shows Up in the Death Rate? Right?
20: Still Semaphoring, Even From the Bottom of the Swimming Pool
19: Time to Sing the Alma Mater
19: Drug Companies Are Polar Bears? Maybe Not.
19: The PhRMA Deal
18: H-h-h-holy C-c-c-c-cow
18: Schematic Notation for Biology?
17: PhRMA's Negotiating Game
14: Spray-Painted For Success
13: Animal Testing: A View From the Labs
12: Sulfoxides: A Sneaking Affection
11: Dealing With Hedgehog Screening Results
11: Animal Rights, You Say?
10: Blogroll Update
10: Pharma's Return on Investment: Yikes
07: How A Real Drug Industry Project Meeting Goes
06: Ghostwriting
05: Just Give It to NIH
05: How Not To Do It: The Secret Patent Decoder Ring
04: Wasted Money, Wasted Time?
03: Savient Feels The Pains of Gout

July 2009
31: Where Drugs Come From, and How. Once More, With A Roll of the Eyes
30: Health Care Reform - Really?
29: Return From Travel: A Note About Cheaptickets.com
27: Travel Continues. . .
22: Travel
20: Amyloid in Trouble
20: Everything In Its Place
17: Drug Approvals, Natural And Unnatural
16: The Further In You Go, The Bigger It Gets
15: Why Does Screening Work At All? (Free Business Proposal Included!)
14: RUR
13: Incompetence, Avoided?
10: Iran: Politics and Technology Update
10: mTOR, Rapamycin, and Lifespan: A Startling Study
09: Too Many Scientists?
08: How Much Does the Drug Industry Spend on Marketing?
07: What's So Special About Ribose?
07: Another Thing We Don't Know
06: Argumentum ad Crumenam
06: Farewell to Hard Copies
03: Day Off
02: Jargon Will Save Us All
01: Blogroll Update
01: Vanda Comes Back From the Dead

June 2009
30: Voluntary, You Say?
30: Devils, Metals, and Details
29: Eli Lilly Gives It Away
26: Snort Yourself Some Zinc. Or Maybe Not.
25: What's With Those People at Elsevier, Anyway?
24: Meanwhile, Over At Sanofi-Aventis. . .
24: GSK's Getting Better. Just Ask the CEO.
23: Proxy Server Update
23: Medarex, Ipilimumab, Prostate Cancer, And Reality
23: One. . .Billion. . .Dollars!
22: Funky Carbocycles
22: Genzyme's Virus Problems
19: Proxies and Politics Again
19: More Hot Air From Me on Screening
18: Professors Patent Pathways and Possibly Profit? Please.
17: Politics: Proxy Servers Revisited
17: The View From Pfizer's Corner Offices
16: Proxies for Iran (More Politics - Mixed With Technology)
15: Ugliness Defined
15: Don't Make Them in the First Place?
14: And Now Some Politics
12: Selling Zyprexa
12: Another Sack of Raving Nonsense Is Slated For Publication
11: Things I Won't Work WIth: Thioacetone
10: Word For Word - But Why?
10: Random Questions, Answered Randomly
09: Instant Med-Chem Wisdom
09: Avastin's Numbers
08: Quick Blogroll Update
08: Rolofylline Hits the Skids
05: Live-Blogging A Conference: Trouble?
05: Blog Contestification
04: Perpetual Patents: A Nasty Thought Occurs
04: CafePharma Will Now Approach The Bench
04: Perpetual Patent Motion Machine
03: Will The Gentleman With the Pitchfork Please Speak Up?
03: Random Questions
02: Blog Contestiness
02: A Deuterium Deal
01: Akt and Mek, But Not PDQ

May 2009
29: Ever Have One of Those Days?
29: Brief Items: Chem Wiki, Autism/Vaccines, Solar Cells
29: Wait For It. . .Wait For It. . .
28: Deuterated Drugs: The PTO Says OK, So Far
28: A Science Writing Award
27: Homeopathic Merchants Take Your Questions! Well, Sort Of.
27: Surfin' On The Surface
26: On the Uselessness of the MSDS
22: Blowups Happen
22: Arena, Lorcaserin, and the FDA
21: J&J Lowers the Boom
21: The NIH Takes the Plunge
20: Mipomersen - It Still Works
20: But You Can't Make Them Take It?
19: Want To Screen Pfizer's Compounds? Sign Here.
19: TMS Reagents: Handle With Care!
18: Arena / Lorcaserin Update
18: San Francisco Biotech: Holding Up, or Not?
15: Competing (And Competing Unethically?)
14: TMS Diazomethane: Update On a Fatality
14: Surrogate Markers Are Awful, But They're Ours
14: Goldman Sachs: Out Of the Drug Funding Business Already?
13: Takeda Evaluating Scientists on "Quality"?
13: Exercise and Vitamins: Now, Wait A Minute. . .
12: Book Review Department
12: Kumbaya
11: Still More Blogroll Additions
11: Merck, Elsevier, and Fakery
08: Blogroll Update
08: Altermune - Real Stuff or Not?
07: Angiogenesis Inhibitors: Helping or Hurting?
06: Into the Clinic. And Right Back Out.
05: Farewell to ACAT, and to Lots of Time and Money, Too
04: Writing With Triazoles
01: Genentech: Let's Hope He's Right
01: Niacin, No Longer Red-Faced?

April 2009
30: Faking It on Facebook
30: Dendreon's Stock: What the Hey?
29: No MAGIC Involved
28: Dear Dr. Derek. . .
27: Don't Hit The Bunkers Just Yet
20: More Travel!
17: Genes to Diseases: Hard Work, You Say?
16: Your Paper (That Sack of Raving Nonsense) Has Been Accepted!
16: Deuterated Drugs: A Side Effect Already?
15: Sheesh
15: Roche Starts to Manage Things
14: Dendreon's Revenge?
14: Who They?
13: An HIV Drug. Or A Gout Drug? Or Both. . .
09: Ariad's Patent: Let Us Now Dance In Circles
08: Pfizer's New Structure: Good Luck To All
07: Biogen Idec: What's Going On?
07: Scientists Running Your Drug Company?
06: San Diego
06: Travel
03: The Mechanical Chemist?
02: The Polypill Rides Again
01: Sponsor A Gene?
01: Mexican Lemons To the Rescue

March 2009
31: A DPP-IV Compound Makes It Through
31: Another Obesity Drug? Not Likely.
30: Lilly's Latest Loses (This Time)
27: Layoffs At Merck
26: Fan Mail
26: The Motions of a Protein
25: Two! Two! Two Drugs in One!
24: Grabbing Onto A Protein's Surface
23: And While We're Talking About Industry-Sponsored Studies. . .
23: (Don't) Trust And (Don't) Verify
22: Blogs and Journalism
20: What Results Did You Have In Mind?
20: Drug Industry Research: Reliable or Not?
19: Fraud: How, and Why, and How Again
18: Things I Won't Work With: Chalcogen Polyazides
17: Takeda Gets A Surprise
16: The Equipment Graveyard
13: "I’d Like to Structure This Transaction So That My Lunch Buys Me"
13: And That Is That
13: Drugs For Bacteria: Really That Hard, Or Not?
12: Greedy Biotechs?
12: Roche / Genentech: The Chase Is Over
11: A Quick Quiz (Re: Antibacterials)
11: Bacteria: Respect Must Be Paid
10: Don't Like It? Well, Just Don't Cite It!
10: Merck/Schering-Plough: Waiting for J&J To Raise Their Hand
09: The Merck Deal and the SEC: Not a Joke
09: Merck Actually Does It
06: Tie Me Molecule Down, Sport
05: More on Wyeth v. Levine and Preemption
05: Your Temperamental Diva Reactions
04: Wyeth v. Levine: Pre-emption Goes Away
04: Gene Expression: You Haven't Been Thinking Big Enough?
03: How Good (or Bad?) Are Patent Procedures, Anyway?
02: Hot Chemistry, Low Tech to High

February 2009
27: Your Paper Is A Sack Of Raving Nonsense. Thank You.
26: Ranbaxy in Trouble
26: Does Glucophage Make Alzheimer's Worse?
25: Single, Simple Numbers: Use At Your Own Risk
25: Inspiration Is Where You Find It
24: Structure-Activity: Lather, Rinse, and Repeat
23: The Limits of Free Scientist Chow?
23: Genentech's Culture: At Risk or Not?
20: Hexacyclinol - Another Request
19: Hexacyclinol: A Forensic Case
18: Business Books: The Enantiomers
18: Supplies of Suppliers
17: Heavy Atoms, Heavy Profits?
16: Day Off
13: A Cure for the Common Cold? Don't. . .Ah, Hold Your Breath
12: Want A Hard Disease Target? Try Lupus
12: Autism and Vaccines: Boiling Over Yet Again
11: A Med-Chem Book Recommendation
11: Kinases: Hot or Not?
10: Do Scientists Read Business Books? (Plus: Add a Circle to Dante's Inferno!)
10: Roche / Genentech: So There is a Deadline
09: Maribavir, Ouch
09: We Won't Stay Off The Radar Screen For Long, Y'Know
09: How Long Is Roche Prepared to Wait?
06: Short Business Notes: AstraZeneca, Biogen, Vertex
06: Prep TLC: The Good Old Days Live On
05: Short Business Note: GSK's At Least Not Going to Merge
05: Sir James Black Vents, Therapeutically
04: Fancy Building, Fancy Science?
03: Their Crime? Collaborating With Other Scientists. . .
03: The Original Nanotechnology
02: Short Business Notes: Roche/Genentech, Sanofi-Aventis, GSK
02: Open Pharma?

January 2009
30: Roche Goes Hostile - Or Does It?
30: 10,000 Hours To Drug Discovery?
29: "I Will Cherish the Personally Autographed Book Forever. . ."
29: Opportunity Costs
28: Science and Its Values
27: Pfizer and the Credit Crunch
27: A Long Tail Indeed
26: Pfizer / Wyeth: Different This Time?
23: The Real Hazards of the Lab
23: Pfizer / Wyeth: They're Going to Take Us All Down With Them
22: The Great Acetonitrile Shortage
21: Nitromed: Someone Wants Them
21: The Hideous Numbers of Compounds
20: Diversity-Oriented Synthesis: Oriented The Right Way?
19: Ten Years After: The Genomics Frenzy
16: Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
16: With A Straight Face, Yet
15: The Blogroll
15: Lilly Pays the Price
14: Qi Gong and Placebo Effects
13: More on Pfizer's Layoffs
13: Lack of Experience, You Know
12: An Alternative Prescription From Chopra, Roy, and Weil
09: Poor Equipment Revisited
09: The Perils of Poor Equipment
08: Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
07: Things I Won't Work With: Azidotetrazolate Salts
07: New Chemistry
06: Why Pfizer?
06: Pharmalot Is No More
05: Well, Hose Me Down. . .
05: New Year - I Hope!

December 2008
23: Holiday Break
22: Publish Your Work The Easy Way
19: My Compound Goes Where the Wild Goose Goes
18: When Placebos Were All There Were
17: Awkward Conversations
16: Layoffs. More Layoffs.
15: Insider Trading in Drug Stocks? Not Unknown. . .
12: The Worst Biotech CEO?
11: Pfizer's Restructuring Grinds Along
10: Floppiness Is Not Your Friend: Who Knew?
09: Goldman Sachs: A New Drug Research Model?
08: Enhancing the Brain: Here We Go
05: Squinting At The Pictures, The Modern Way
04: Curse Of the Lost Compounds
03: Roche Stalls For Time
02: Torcetrapib: What Was the Problem? And Does It Matter?
01: Prodrugs: How the Pros Do It?

November 2008
26: How Slow is Research Today? Here's a Recipe!
25: Avandia: Trouble, Run Head to Head
24: Two Drugs in One? Maybe Not.
21: The Back Door to the Stock Market
20: Noisy Numbers
19: Novartis and Reality
18: Cheese Dip and Hydrochloric Acid
17: Liable For Generics? You Are Now!
14: Sticking It to Proteins
13: The Yield Monster - And Its Friend, The Model Monster
12: Crestor: Would It Save Any Lives?
11: Wash Your Tubes; Mess Up Your Data
10: Crestor: Risks Up, Risks Down
07: System Biology: Ready, or Not?
06: CB-1 Obesity Drugs: Farewell to the Whole Lot
05: We Now Return to Our Regularly Scheduled Program
04: We Interrupt This Science. . .For Some Politics
03: Pfizer: Strategy, Layoffs, and Money

October 2008
31: Fructose In The Brain?
30: Lilly And Imclone: Not Expensive Enough!
29: Cutbacks - But Not As Bad This Time
28: Out the Door and Down the Stairs
27: Publish And Be Damned, Most Likely
24: BlackLight Power Responds
23: Merck Cuts Back (Again)
22: Blacklight Power: What on Earth?
21: Things I Won't Work With: Triazadienyl Fluoride
20: Fearful Symmetry?
17: Down The Chute in Phase III
16: Animal Models: How High to Set the Bar?
15: Where Are the Drugs?
14: Impact Factors: Can We Pretend That They Don't Exist?
13: Old School - Really Old
10: Kevin Trudeau: A Bit of Good News
09: More Glowing Cells: Chemistry Comes Through Again
08: A Green Fluorescent Nobel Prize
07: Nobel Season 2008
06: Imclone Really Does Get Bought
03: Day Off
02: Taranabant Is No More
02: Eli Lilly and Imclone: Sensible? Real?
01: Hard Times: A Manifesto

September 2008
30: Various Drug Industry News, None of It All That Good
29: Why Don't You Just. . .
26: Prasugrel Today?
26: Imclone's Secret Admirer
25: Pfizer: As We Speak?
25: Protein Folding: Complexity to Make More Complexity?
24: Ariad's Patent: A Court Rules
23: You Call That An X-Ray Source?
22: More Than This
19: Sunesis: No Substitutions Allowed?
17: Sugars: Still Crazy After All These Years
17: Ranbaxy: Cutting Corners, or Falsely Accused?
16: Neil Bartlett, 1932-2008
15: Extracting Money From Matthias Rath, For A Change
12: BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
11: US and UK Biotech: Growth and Form
10: Pfizer / Bayer?
09: Antipsychotics: Do They Work For A Completely Different Reason?
08: The Complicated Causes of Cancer
05: Samurai! Unleash Your Drug Candidates!
04: X-Ray Structures: Handle With Care
03: Direct To Consumer Ads: Wasted Money?

August 2008
29: Sticky Containers, Vanishing Drugs
28: PNAS: Read It, or Not?
27: Crowded Proteins
26: New, Improved DNA?
25: How Not To Do It: Water Aspirators
22: Open Source Science?
21: RNAi: Bubble or Not?
20: Replacing What's Being Lost
19: Fighting Boredom, Profitably
18: Genentech and Roche, Act Two
15: Back
05: Roche Palo Alto: What's Going On?
05: Time Off
04: Job Seekers: Genentech, GSK, and Elsewhere
01: GSK Layoffs: Yes, Again

July 2008
31: Rember for Alzheimer's: Methylene Blue's Comeback
30: Bapineuzumab: Good For Anything or Not?
29: Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
28: Questions You Don't Necessarily Want the Answers To . . .
25: Should Genentech Be a Part of Roche?
24: Confident
23: Patents Stopping an Alzheimer's Wonder Drug?
22: Vytorin: Another Round of Nasty Results
21: Backtracking, Necessary and Unnecessary
18: Lowe's Law of Diurnal Distribution
16: Receptors: Can't Live With 'Em, Can't Understand 'Em
15: Metabolic Hope Springs Eternal
14: Things I Won't Work With: Cyanogen Azide
11: Sharing the Enlightenment
10: More on Outsourcing
09: How's The New Boss Doing?
08: Glaxo Asks the Eurocrats
07: Pfizer's Prospects: Just Ducky
04: Happy Fourth of July
03: I Can Has Ugly Molecules?
02: More Pfizer Layoffs?
01: Leaving Comments: A Fix
01: The Gates Foundation: Dissatisfied With Results?

June 2008
30: Another Alzheimer's Compound Goes Down
27: Unknown - But You Can Buy It
26: Funding in the EU: The Simple Way
25: (No) Anarchy in the EU: A Report From Inside
24: Prasugrel: Come Back This Fall
23: Auroral Activity
19: Anarchy in the EU
18: All The Fat Cells You'll Ever Have - Sort Of
17: Protecting Amyloid's Parent?
16: Alli: "Underwhelming"
13: Elan Tries Again
12: Suits vs. Lab Coats?
11: More On the GSK Layoffs
10: GSK: Money-Green Outside, Pink-Slip Inside
09: An Impressive Nanolist of Nanocitations
06: Resveratrol in Mice
05: Merck, Vioxx: Seventeen and Three
04: Tote That Barge, Lift That Bale
03: Oops
02: A Breath of Fresh Air from Fuji

May 2008
30: Ah, Glassware
29: Nullius in Verba
28: Awash in Yen
27: An Eye For the Numbers
23: Up Close and Personal
22: Killing Proteins Wholesale
21: Lurching Around For Fun and Profit
20: The Miracle Solvent
19: Empty As Can Be
16: Nanotech Stem Cells, Order Now!
15: Copper: A Gentleman's Disagreement
14: Summer Student Time
13: In Which I Hate A Wonder Drug
12: Explaining It All
08: Merck Bails on Natural Products
07: Science By Country
06: Alzheimer's: A Report From the Front
05: Naming of Names
02: "Not Useful" Means "Not Approvable", Right?
01: O Pioneers!

April 2008
30: How Not To Do It: Diazomethane
29: Cordaptive Q and A
28: A Salute
25: Why Buy, Anyway?
24: $720 Million Worth of Sirtuin Research
20: Quick Note
18: Cut It Out. Cut It Out Now.
17: Getting Smarter Already?
16: Fun With Bacteria
15: Walk Around Some
14: Fifteen Minutes Shot
14: A Meditation on Solvents
11: Free Sushi in the Cafeteria!
10: Exubera, Safety, and No Guarantees
09: And You Thought Exubera Was A Disaster Before
09: Another Pop Quiz!
08: Fun With Tunichromes
07: Pre-emption For Real?
04: Another Cholesterol Medication Goes Down (Or Does It)?
03: Whose Guess Is Better?
02: Vytorin Numbers
01: Vytorin: It's A Pity

March 2008
31: Writing It Down
28: RNA Interference: Even Trickier Than You Thought
27: Start Small, Start Right
26: The Lucky Bonus Pack
25: Getting To Lyrica
24: That's Never Gonna Work
21: Pfizer Loses, So Far
20: Anonymity?
19: Now Your Liver Doesn't Have to Make It For You
18: A Solution, Courtesy of the MIT Faculty
17: You Get What You Pay For?
14: Pen and Paper
13: Pfizer vs. the NEJM: A Legal Showdown
12: Taranabant in Trouble?
10: Fill Out Your Pharma Brackets
10: Hits, Misses, and Some More Misses
07: Dissolve Your Troubles Away
06: Fakery And Its Ends
05: Smaller, Wetter, Harder to Work With
04: Off Target? Which Target Did You Mean?
03: Big Steaming Heaps of Fraud

February 2008
29: How Not To Do It: Column Chromatography
28: ApoE4: Test or Not?
27: Antidepressants: Depressing News or Not?
26: Sand Won't Save You This Time
25: More On Merck and Taranabant
21: New Tricks With Glassware
20: What You Become Known For
19: Day Off
15: Putting Out the Inevitable Fires
14: Getting Real With Real Cells
13: One Time Only. Or Maybe Just a Few.
12: DNA Forklifts, DNA Pliers
11: Fast Plaques in a Slow Disease
08: A Look Under the Hood
07: Write It Down, Write it Down
06: Dig the New Breed
05: Room At The Bottom, For Sure
04: How Many PPIs Does the World Need?
01: Commenting Issues
01: A Few Questions For My Fellow Pharma Chemists

January 2008
31: Drugs and Money
30: Recycle, Reuse, Republish
29: The Animal Testing Hierarchy
28: Laissez-Faire?
25: Extractions: A Way of Life
24: Cheap Happiness
23: Making the Adjustment to Smallness
22: These Fragments I Have Shored Against My Ruins
21: Breaking the Contract of Aging
18: Eat It, Breath It, Soak in It?
17: The EU Suspects No One, And Suspects Everyone
16: Judah Folkman
14: Vytorin, Holed Under the Waterline
11: They Can Be Ranked - Somehow
10: Drugs and Money and How It Feels
09: Ah, Politics
08: Rainbows and Fishing Expeditions
06: Dollar, Drugs, and Advertising
04: Plants For Cancer?
03: Top of the Heap
02: Back On the Air

December 2007
21: Winterize Your Ideas
20: Snow Day
19: Scrape Off Some Attitude
18: Hearing Footsteps
17: Le Dernier Cri
14: Biogen's Not For Buying. For Now.
13: Underperforming Triple Bonds
12: Med-Chem Layoffs, On the Front Page
11: A Bad Assay: Better Than None?
10: More Belts Tighten
07: Kids These Days!
05: Avandia: Going Under for the Third Time?
05: Unacceptable
03: The Big and the Little
03: Exciting Nonsense Wins Another One

November 2007
29: Neat! Wish It Were True!
28: Bad Luck For Novartis - And For Diabetics
27: Then I Felt Like Some Watcher of the Skies. . .
26: Still and All
25: You Do The Easy Stuff; I'll Do the Easier
21: Synthetic Prep of the Day: Chocolate Pecan Pie
21: Holiday Break
20: And It Goes Like This!
19: Depressing Figures for Acomplia
15: Quiz Time!
15: And Speaking of Discovering Things. . .
15: Maybe Not Improved, But Definitely New
14: How You Doin'? How's Everybody Doin'?
12: Here Be Chiral Dragons, With Fluorinated Fangs
11: A Real Genetic Headscratcher
09: One Year
08: Dumber in English?
07: Reasons to Be Different
06: Lights, Camera, Pharma!
06: Andy Grove: Rich, Famous, Smart and Wrong
05: Bright Lights and Applause?
04: Nerve, Lots and Lots of Nerve
02: One For the Brave

October 2007
31: Resistant Little Creatures
31: How Not to Do It: Hydrogen Bromide
29: What We Don't Know About Enzymes
29: Bacterial Infection: Better Or Worse Than Cancer?
25: Looking Backwards
24: Come On. Improve, Already.
23: Vial Thirty-Three, And More
22: Surveying the Exubera Crater
18: Understanding Dawns
17: Biogen on the Block?
16: Three Things You Need
15: Checking The Numbers on the Alzheimer's Test
15: Enzyme Humility
12: Unnatural, And Proud Of It
11: Let Us Now Turn To the Example of Yo' Mama
10: Ertl Wins: Down With Witchcraft
09: Nobel Chemistry Odds
09: Blogroll Update
08: Nobel Season
04: No Problem At All
03: More Layoffs, And What They Might Mean
02: Why Now, And Not Before?
01: All Sorts of Holes

September 2007
30: If Not This, What?
27: Thimerosal. Again.
26: Expensive Reading
25: Hey, Graduates! Negotiate Hard, You Hear, Now?
24: More Sirtuins With More Effects
24: Good News From the HR Department!
20: Go With The Er, Flow?
19: Fixing the Patent System?
19: The Good Old CombiChem Days
18: Ugly, But Useful
17: Arsenic, Patents, and the World
13: Don't Step Over It, Even If It's Right in Front of You
12: Drugs From Where?
11: Fresh Air, Or What Passes For It
10: Have We Got A Deal For You!
09: Guess That Market
06: Aromatherapy
06: More Things Than Are Dreamt Of
02: Renin, Wherefore Art Thou, Renin?

August 2007
31: Here It Goes
30: Elbow Room
28: Like Clockwork
27: Oh, Come On
26: Cheer Up
23: ". . . Jobs That Don't Exist"
21: Sorting Through the Piles
21: Ah, Rumors
20: The Current Cancer Long-Jump Record
17: More on Interview Seminars
14: Winning, By Tying Losers Together
13: Pilferage
12: These You Shall Have Always With You
09: Buying What You Can't Make? Or What?
08: Steve Ley, Azadirachtin, and Me (Very Much in That Order)
08: Exubera Spirals Toward the Drainpipe
07: Meet the Blogger?
06: Here, Fix This, Would You?
05: The Choir Hears It Again
03: Not Necessarily So
01: Run! Anthropologists!

July 2007
31: Incomprehension, Out For A Stroll
30: Avandia's Latest Round
27: You Discover It, We Sell It. Deal?
25: From the Sequencer to the Drugstore?
24: Godzilla vs. Mothra? Relman vs. Epstein!
23: Deactivation, After All
22: A Farewell to Tin
19: Hype In Spaaaace!
18: Over There, Behind That Stack of Whatchamacallits
17: Visfatin: Real Or Not?
16: European Drugs, American Drugs
15: Proteomics 101
13: Pour Encourager Les Autres
11: First Impressions
10: Travels In Numerica Deserta
09: Now With Ethyl Mesylate!
08: Starting Up Again

June 2007
26: Two Weeks Off
21: Real Life, Which Costs Real Money
20: Bigger, Tougher, Longer? Or Not?
18: Right Down the Alli
17: Access To Science
15: Rimonabant: Down to Earth
11: Rimonabant, Out In the Light
07: The Chamber of DNA Secrets
06: Massachusetts Moving
06: A Post I've Been Looking Forward to For Months
04: Phase Zero?
03: Pecunia Non Olet?

May 2007
31: The Avandia Wars Continue
29: Knowing What You Know. . .
25: More Avandia, And More on Marketing
24: Avandia: Trouble or Not?
23: Exalted Paper
22: Evolution In Action
20: Little, Big
18: But Enough About You
17: Beta-Secretase: Not So Fast?
16: Sunbeams, Single Electrons, and You
15: Into The Trackless Wilderness
14: Safer Every Day!
10: Alas, Dendreon
09: A New FDA?
09: Blogroll Update
07: Nonsense. On Stilts. Playing a Trumpet.
07: Brazil Raises The Pirate Flag
03: Forewarned is Forearmed
02: Obvious Ain't Obvious No More

April 2007
30: Outsourcing Blues?
29: Time To Conduct Some Business
26: Less Than Zero
25: A New HIV Therapy. Yawn?
24: Put Your Money Down
22: Melting Keys and Squishy Locks
20: Worst Animal Model: Nominations Are Open
19: Let A Thousand Flowers Bloom
19: The Big Time
18: Cro-MagnonDraw
17: The Doctorate and Its Discontents
15: Doctorate or Not?
13: Deep Breaths
12: Layoffs - Again
11: Exubera: This Time With Feeling
11: Amgen: The Pythian Oracle Laughs Again
10: Sulfur, Your Pal. Mostly.
08: Buy! Sell! Shout! Moan!
05: Awful, No Doubt. But Not As Awful as Before?
04: Linkage!
03: Vaccines Everywhere
02: Failure: Not Your Friend, But Definitely Your Companion
01: The HDL Compost Pile

March 2007
30: Rimonabant, Slowly
29: I Want A New Nitro
27: ACS Meetings
26: Vectibix Lurches A Bit
25: Wandering Through the Hydrides
23: Naked Synthesis
22: FDA Advisory Panels: Pay, No Play
20: AGI-1067: Dead or Alive?
19: Scientists, All Over
15: Lousy Reactions: Reader's Choice
14: Schering-Plough Goes Shopping
12: No Shortcuts
11: More Help Wanted?
08: How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
07: Fish Nor Fowl?
07: Quietly Disappearing From the Skies
06: Decisions, Decisions
04: Calcium: A Backwater
01: How Not to Do It: Tertiary Butyllithium

February 2007
28: Have We Got a Job For You!
27: Wrong, But Still Convincing
26: Hedgehogs in Stockholm
25: Biotech's Net Loss?
23: F. A. Cotton, 1930-2007
22: Inspirational Reading?
22: Back From DC
21: CMPI Conference: Critical Path
21: CMPI Conference: CATIE and ALLHAT
21: CMPI Conference: Lunch With the FDA
21: CMPI Conference: Panel on the Politics of Drug Evaluation
21: CMPI Conference: Panel on Media Coverage
20: Something From Nothing
19: You Want Me to Just Talk? No Problem.
18: Wake Up and Smell the Solvents
16: Comments on Comments
14: Gene Patents, Part One: Genes As Chemicals
13: Crichton, Patents, and Genes
12: A Good Day's Work
12: Good Sense Breaks Out, Film at Eleven?
08: Depraved and Deprived
07: There's Toxicity and There's Toxicity
07: Vertex, Hepatitis, and Gripping the Arms of Your Chair
05: Good Mistakes?
05: A Break, Whether I Felt Like It Or Not
04: Going Hollywood, For Our Own Good?
01: How Not To Do It: Ruining Stuff

January 2007
30: BMY-SNY?
29: Open For Business
29: Blogroll Update
28: What Can Academia Do?
25: The Big Picture
25: Way Out Here
24: Back on the Air
17: Pfizer's Pfinances
16: How Not to Do It: Sophomore Organic Edition
15: Novo Nordisk Axes Med-Chem
14: Problems and Solutions
12: Ghost Town
11: An Innocent Question
10: Upside Down Activity
10: Reality, Here In This Little Dish
09: That Smell
08: PLoS One
07: Good Stuff and Bad Stuff
04: Take Your Shots (For Real, This Time?)
03: You'll Be Safe Under Here. Maybe.
02: That Can't Be Right - Try Again
02: And The Winner Is. . .
02: Out With the Old

December 2006
28: Cleans Down to What Should Be the Shine
26: Work At Home! It's Easy; It's Fun!
21: Holiday Schedule
20: Injustice
19: Hi, My Name Is [...]
18: ICOS In Pieces?
14: Love and Anger
13: Ars Longa, But Instructions to Authors Say "Brevis"
11: Torcetrapib: The Foil-Lined Hat Perspective
11: Old School? Same School!
08: Shameless Self-Promotion
07: Are You Experienced?
06: Bigger And Greasier
04: Too Near the Sun?
03: The Torcetrapib Catastrophe
01: Pfizer's Sizing

November 2006
30: The Other Side of the Table
29: Bad Interviews
27: The Litvinenko Case: More On Polonium and Alpha Particles
27: Polonium Poisoning
21: The Paper Mountain
20: Sell! (It's Not Just Me)
17: Ah, the Heck With the Error Bars
15: Vial Thirty-Three: Warp Drive
14: Where Do All The Chemicals Go?
14: Elsewhere
13: The Race Is On
10: Publish, Then Perish
09: Help Wanted - I Hope
08: Watch This Space
08: Links and Such
06: It Went Up Instead of Down
06: Chinese Med-Chem - In China, For Once
02: Hope, Springing Eternal And All That
01: And Thee, O Time
01: You Can't Make Money If You Don't Get Paid

October 2006
30: Blow The Trumpets
29: Family Portraits
26: It Should Work. It Just Doesn't.
25: Mass Spec on Mars
24: Naming of Names
23: Experimental Compound Codes
22: The Unattractive Truth
19: Levoglucosan
18: Peptides as Texts
17: Up Periscope And Fire All Bow Tubes
16: Show What You Know
15: German, Anyone?
12: More Handedness
11: On The Other Hand
10: Five Things I Haven't Used in Years
09: Forty NMR Magnets and 3000 Proteins Later. . .
09: Here and There
05: The Inscrutable French
04: Cheer Up, You Chemists
04: Another Chemistry Prize for Biology
03: Neuropeptide Y Dies, But It Never Surrenders
02: RNA Interference: Film at Eleven
02: Nobel Update: RNAi Wins
01: Test Your Skills!

September 2006
28: The Horse Latitudes
27: Nobel Fever Is Upon Us
26: Smell the Vibrations
25: A Spray-Painted Crystal Ball
24: Touch Me Not
22: Darn Photons
20: Imclone, Drama Queen of Biotech
19: By Any Other Name
18: Tenderbutton Calls It Quits
17: Tough Targets
14: Take Your Shots
13: Spectroscopic Days
12: Walking the Plank at Bristol-Myers Squibb
11: Enzymes Do Whatever They Want To
10: If You Want Your Explanations Overnight, It'll Cost You
07: Inherently Obvious - It's Obviously Inherent
07: Move On, Move On - Nothing To See Here. . .
06: Tell 'Em You Work On Something Else
05: Ariad's Patent Eviscerated
04: Plavix Plot Twists
01: Merck: Unfigure-outable

August 2006
30: Those Darn Invisible Creatures
29: Evil Thoughts of Evil Things
28: Paper on a Shelf
27: Floyd Landis: Could His Cortisone Treatments Exonerate Him?
24: Respect! Honor! Recognition! All For $149.95!
22: Explain This, Hot Shot!
15: Kevin Trudeau Was Born in 1963
15: Here and There
14: Tegenero, In Detail
13: Six Chem-Geek Questions
10: The Great Plavix Disaster
10: Airplanes and Chemicals
09: Ray Kurzweil's Future
08: Back in Court With Ariad and Lilly
07: A Vaccine Against Putting on Weight?
06: Where Do They Come From?
03: The Last Word on Eerie Glowing Labs
02: A Law of the Lab: Yields and Variations
01: Testosterone, Carbon Isotopes, and Floyd Landis

July 2006
31: Hobson's Choice
30: Pfizer's Man at the Top
27: Good News, Now That I Think About It!
26: Pfizer Recalculates
25: The Sun Shines at Pfizer
25: Back To Life
23: Hexacyclinol Rides Again
20: Peptide Craziness
19: Fuzeon's Fallout
18: Getting and Spending
17: Pounding Sand
16: The Future is Unwritten
13: A Friday Linkfest
13: J&J Shrinks Their Labs Again
11: More Purple Radiance
10: Aluminum: Friend or Foe?
09: Down the Chute: Your Call
07: Memo to the Public Relations Department
05: More Statin Skirmishing
04: Now With the Great Taste of Fish!
03: Pyrotechnic Days

June 2006
29: Rimonabant Arrives
28: Part Nine Hundred and Forty Two in a Series. . .
27: Academia in Summertime
26: Vioxx: 18 Months to Trouble?
25: Neurocrine's Choice
22: To The Third Darn Decimal Place
21: Waste O' Time Awards
20: Formally Undecideable
19: Rats Rule, Right?
18: More on Voodoo
15: And 0.04 Molar in Eye of Newt. . .
14: Vox Populi
13: The Fur Continues to Fly
13: Disapproval of Approvability
11: What's German For "Food Fight"?
11: Vial Thirty-Three: The Third Run
08: Peter Kim, So Far
07: Best When Used By. . .
06: Vial Thirty-Three Rides Again
06: Vial Thirty-Three: One Up, One Down
05: Hexacyclinol? Or Not?
04: Resistance Isn't Quite Futile
02: Brief Political Interlude
01: That Fount of Information We Call ASCO

May 2006
31: As Merck Caroms Off Another Tree
30: Things I Won't Work With: Frisky Perchlorates
29: Ask Not
25: Too Big to Discover Anything
25: Back on the Air
23: Can't Buy These Thrills
22: Merck and the Numbers
22: Mid-day Update
21: Chem-Geek Alternate History
20: Minute by Minute
18: A Question For the Crowd
18: Vial Number Thirty-Three
17: Merck's Latest Underwhelming Data
16: The New England Journal And Its PR Flacks
15: Leadership Secrets of the Data Fudgers
14: Cliff Diving
11: A Day at the Rota-Vap
10: A New Route to Tamiflu?
09: Ends, Means, Rats, and Dogs
08: A Natural Wonder Drug - Now What?
07: Yet Another Law
04: Ariad Wins a Round
03: Access to Phase I Drugs: A Constitutional Right?
03: Full Disclosure
03: Have The Rules Changed?
02: Things I'm Glad I Don't Do: Isolating Ciguatoxin
02: Travel

April 2006
30: All Natural
27: Golden Parachute, Still Packed and Ready
26: Jungle Rot
25: A Shot Across the Bow
24: Merck, So Far
23: You Can't Win If You Don't Play
20: Sulfurous Stenches: A Connisseur's Guide
19: Why All the Gloom?
18: There Is a Tide. . .
17: Reading Our Own Press Releases
16: Don't Know. Don't Care?
12: The Process of Process
11: Ariad's Day in Court
10: Linkorama
09: New Frontiers in Self-Deception
06: How Not to Do It: Distilling HMPA
05: Which World Do We Live In, Anyway?
04: Once More Into the Patent Breech
03: More On Doing Away With Patents
02: Down With Patents, Eh?

March 2006
30: Give The People What They Want
30: Missed One!
28: Rioting for Unemployment
27: Cleaning Out the Hood: An Internal Monologue
26: A Word to the Wise About TGN1412
24: Explosion News
24: Can You Say "Uebernahmeangebot"?
23: Crystals of Doubt
22: A Lengthy Day
21: Nitromed's Slow Decline
20: Grad School, Blogged
20: TNG1412: Was There a Warning?
17: Update on TGN1412
16: Price Gouging or Not?
15: No Immunity From Immunity
14: Neowater Replies
13: The Big Statin Pillow Fight
12: Bubble Fusion Implodes
09: Wonder Drug, Indeed
09: Men and Women and Science and Jobs
08: How Not to Do It: Liquid Nitrogen Tanks
08: Things Turn Nasty
06: Man Hands on Misery to Man
05: Journal of Biological Chemical Biochemical Chemical Biology
02: Technical Difficulties
02: Procter and Gamble Throws in the Towel
01: Deception Begins at Home

February 2006
28: More on Outsourcing
27: But At My Back I Always Hear. . .
26: Tied to the Mast
24: What's French for "Trust Us"?
23: Blogroll Revamp
22: NEJM vs. Its Contributors, Round Two
21: Gold and Lasers
20: Rimonabant Bangs Into. . .Something
19: Because I Never Lie, and I'm Always Right
16: What's It Worth to You?
15: Pfizer Takes a Deep Breath
14: First Slide, Please
13: Heart-Warming Stories of Success
12: Kinase Inhibitors: Doomed From the Start?
09: Ban Intelligent Design?
08: Garnier Strikes Back
07: Return of Neowater
06: J&J Shakes Things Up
05: Stream of Consciousness
02: Nanotech Wonder Water?
01: The Good New Days

January 2006
31: Here's A Shovel. Could You Dig Yourself In Some More?
30: Forecast: Rain, Eventually
29: Name Reactions for One Thousand, Alex
26: Ah, It's Fine. Just Send the Darn Thing Out Already.
25: If It's Not One Thing. . .
24: The Examiner Finally Snaps
23: Merck versus the New England Journal
22: Full Disclosure
19: But His Name Lives On. . .
19: Tamiflu: Good For Anything, Or Not?
18: A Scientific Aptitude Test?
17: Gimme That Old Time Reaction
17: Dangerous Thoughts
16: Various Updates
15: The FDA Loosens Its Tie
13: How Not to Do It: Ether Peroxides
12: Plenty of Tar to Go Around
09: Stem Cell Disaster
08: My Shopping List
05: Ugly, But Effective
04: Mice, Humans, and Cancer
03: Pemoline Problems
03: Comments Welcome - Really
02: A Scientist's Resolutions

December 2005
29: Outside Reading
27: What Makes an Ugly Molecule?
23: Sort Of Like A Wine Cellar
22: Poor Put-Upon Intelligent Design
21: Another Shot at Cancer
20: The Dover Decision Comes Down
20: Does Celebrex Have A Future At All?
17: How Not to Do It: Bromine
15: Attack of the Angry Viruses
14: An Expensive Way Back for Celebrex
13: The New England Journal of Legal Immunity?
13: Grand Rounds
12: Play by Play in the Lab
09: A Vioxx Bomb Drops. Or Does It?
07: The Hard News on Cancer
06: Well-Rounded?
06: Grand Rounds Today, and Next Week
05: Home Sweet Home
04: Not On the Same Page
02: The Bell Finally Tolls for Peter Rost
01: Rigel's Puzzling Failure

November 2005
30: Okadaic Acid Makes Vanity Fair
30: Merck Update
29: Ghrelin and Obestatin
28: Merck, Finally
27: Hire the Thoroughbreds?
25: Instead of Working
22: Serono's Suitors
21: Run, Do Not Walk, To The Nearest Exit
21: Old Standbys
20: Sir2 Surprise
17: A Man, A Book, and a Plan. Several Plans.
16: What Sort of Training?
15: Statin Showdown
14: One Darn Miracle After Another
13: Arcadia's Furnishings
11: Gene to Drug: You Bet
10: . . .And That Settles It
09: Cash For Vaccines
08: University of Drug Discovery?
07: Intelligent Design, Molecule By Molecule
06: The Dover Decision
03: Merck Off the Mat
02: The Flu Plan, Part Two: Antiviral Drugs
02: The Flu Plan, Part One: Vaccines
01: Molecular Modeling Cage Match

October 2005
31: Five Questions
30: Gooooaaaal!
28: Pargluva Goes Down?
27: Imclone Revisited
26: The Latest in Pharmaceutical Technology
25: Start Your Engines
24: Hype or Hope?
23: The Tar Pit Beckons
20: This Had Better Be Good
19: Complaints From a Fossil
19: Procrastination Assistance
18: Waiting for Pargluva
17: James Cramer, Biocryst, and You
16: Matthias Rath, Pioneer
13: Buy! It's More Expensive Than Usual!
12: The Undefeated Brazilian Team
11: The Old Stuff
10: Time and Chance
09: Needs and Wants
06: The Great Divide
06: Outside Reading, and Plenty of It
05: Human Genome Science Hits the Wall
05: Metathesis Nobel!
03: Where Do the Good Ones Go?
03: Well Deserved
02: A Piece of the Action

September 2005
30: And Another Thing. . .
29: The Hazards of Molecular Modeling
28: Clamping Down, or Loosening Up?
27: Tribes
26: Antivirals "Gathering Dust"?
25: Report From What I Think is the Frontier
22: By a Nose in a Head to Head
21: No Clear Winners
20: Say It Again!
19: Klotho: Sooner Than You Think?
18: A Sensitive Guy
15: Pretty Much the Reason You'd Think
15: Here and There
13: It Pours on Ligand
12: ". . .And to Furbish Falsehoods For a Magazine"
11: Remind Me Not to Do This Again
08: Muraglitazar's Turn
07: The Tiniest Doors Begin to Open
06: Ranking the Journals - Try It at Home!
06: Crossing Your Fingers, Authoritatively
01: Thought For a Long Weekend

August 2005
31: More Fun With Impact Factors
30: Our Friend the Impact Factor
29: pHooey
29: Nature Doesn't Care: Latest in a Series
28: Kevin Trudeau's Snake Oil Empire
25: The Painful History of Substance P
24: Having the Hands
23: Outside Reading
23: Gritting Our Teeth
22: Mutual Suspicions
21: Okay, One More Merck Point
21: No More Merck For A Couple of Days
19: Judgement Day
18: Everything's Under Control, Right?
17: No Such Disease
16: For Further Enlightenment
16: Experimental News
15: Out the Door and Over the Edge
14: Blogging About Science Blogging
11: Selectivity: One of Those Flexible Concepts
10: Another Thing You'd Think Would Be Simple
09: Differences Between Academia and Industry, Pt. 4
08: Room At the Top?
07: An Off-Topic Ramble
06: Even More Worthwhile Stuff
04: The Place to Be
03: Let's Check This Blank Page, Here
02: Never Came In Handy. Not Once.
01: Seven Questions

July 2005
31: At Your Newsstand Today
28: Like, Er, Fine Wine. I Hope.
28: A Tale of Two Trials
27: Once And For All
26: Merck on Trial
25: Hydrogenation Made Easy?
25: The Check Shows Up in the Mail. Really.
21: Science Marches On
20: Arr, Me Hearties!
19: Sitting Through Some Chemistry
18: The Leash of the Law
17: And It Goes Like This
09: Summer Hours
07: More on Brazil and Kaletra
06: Brazil Pulls Out the Pin
05: Dinner the Night Before
05: Continued Slacking
03: Happy Fourth of July

June 2005
30: Where's the Combo?
29: Vaccines and Human Folly
28: Cancer Delusions
27: Thimerosal, Again
26: How Not to Do It: Vacuum Pumps
23: News Flash: I May Not Be a Fool
22: Fan Mail
21: Morphine in the Brain: Go For It, or Not?
21: Data, At Last
20: More Brain Surprises
19: What Makes A Target, Anyway?
16: Pfizer Opens Their Wallet - Again
15: How Safe Is This Stuff?
14: Fungal Problems
14: The Research Exemption Lives!
12: How Not to Do It: Distilling Benzene
09: Dr. Rath Does What He Can
08: A Day in the Life of Peter Rost
07: Experimental Update
07: When the Alternative is Nothing
06: A Drug's Target, Finally
05: Biotech At Last, Eh?
02: How Much Success?
01: As Thin As a Soap Bubble

May 2005
31: Modeling the Modelers
30: Tailfins and All
27: Compounds for the Sake of Compounds
25: The Voice of Experience
24: You Figure It Out
23: Intelligent Chemical Design
22: That Has to Be Good, Right?
20: Outside Reading
18: Vertex Turns Over a Winner
17: Very Wrong, or Very Right
16: Days of Silicon and Roses
16: Cuprate Voodoo
13: ASCO Fever
11: Public Utility, You Say?
10: Getting Hired as a PhD
09: Punching the Clock at Merck
08: How To Get Hired: Associate Positions
06: 'Tis the Season
04: Another Law of the Lab
03: Ghostly Influences
02: Merck and Integra Go the Distance
01: Between Friends. Sort of.

April 2005
28: Speak for Themselves, They Do
27: Experimental Update, For Those Who Care
26: Knocking Opportunity Costs
25: What Ails the Germans?
25: Live The Stereotype!
24: The Consolations of Pure Research
21: The Globalization of Med-Chem
20: Sneaking Out for an Interview
19: Getting A Job
18: The Price of Desperation
18: A Smelly Riddle
14: How Good Is Aricept, Anyway?
13: Vaccines by the Dozen
13: A Steeplechase of Dead Horses
13: Do It Again
07: An Update
05: In Memoriam
03: Don't Talk To Yourself So Much

March 2005
31: Why Carbon Matters
30: Lost Arts
30: More on Question Four
28: Targretin's Troubles
27: Ten Questions
23: Drug versus Stock
22: Still Not All That Easy
21: Springtime for Oncology
20: Ancient Metals
17: Symlin, At Last
16: Think Twice
15: Back For More
12: New Address
10: Progress Through Craziness
09: Rewiring the Brain?
08: The Latest from the Fume Hood
07: The Next Science
06: Just How Many Compounds Are We Talking About?
03: Things I Won't Work With: Carbon Diselenide
02: Oh, Dear
01: Too Interesting For Us

February 2005
28: Tysabri's Fall
27: Law Number One
24: Getting a Faster PhD?
23: Exobiochemistry
22: An Antiviral Example
21: Can Med-Chem Help With Bird Flu?
20: COX-2 Aftermath
18: Waiting for the FDA
17: Law and Disorder
16: Dysfunctional Disclosure
16: Glaxo v. Pfizer: Sales Force Stand-Down?
14: Bigger and Greasier
13: Pfizer's Prospects
10: The Bones of the World
09: How'd We End Up Here, Anyway?
08: Maybe They Should Fire Them All?
07: One Problem Solved, Anyway
06: A Technical Question
03: Elbow Room
02: Up There, and Down Here
01: Merck Takes Another One

January 2005
31: Does Your Labmate Have the Hands?
30: Welcome to the World, I Hope
27: Hope in a Drum
26: Glassware Geek
25: The Novartis Way
24: What We Are Pleased to Call State of the Art
23: A Trial Too Far
21: And Now A Word. . .
20: Through the Looking Plastic
19: Bonfire of the Wonder Drugs
18: Model Systems, From Inside and Out
17: Don't Become A Scientist?
16: More on Titan
14: How Often Do We Land on Another World?
13: Samuel Johnson Was Right
12: Our Friend the Nitrogen Atom
11: Right In Front of You
10: The Example of Claritin
10: Success Has A Thousand Fathers
06: More Fun With DNA
05: Like Moving Furniture Across a Tightrope
04: Tadpoles to the Rescue?
03: . . .Nor Am I Out of It
02: Finishing, And Starting

December 2004
29: Schedule Update
27: Back Under the Sheets For Me
23: Holiday Blogging
21: Optioning the Drug Portfolio
21: No Drug Is An Island
19: Boarding Up the Windows
17: The FDA Weighs In
17: Black Friday: One Damn Thing After Another
17: The Other COX-2 Shoe Drops
16: Lab of the Future!
15: Die-oxin?
14: The Coming Oncology
13: Fixing the Drug Industry?
12: Stocking Stuffers, of a Sort
10: An Economist Who Gets It
09: Housecleaning
08: Follow Which Money Where?
08: An Experiment in Progress?
07: Check, Please
07: Alex Tabarrok on Me-Too Drugs
06: Tarceva Targets
05: Beg to Differ
02: Blurry Copies
01: Strangers on a Train

November 2004
30: More on Woodward
29: Archaeologists Announce Dirty Laundry Discovery
28: Some Perspective
23: Chemistry Geekery
23: I Don't See How This Qualifies As Bliss
21: Safe, And Other Four-Letter Words
18: Nine Things I'm Having Trouble Imagining
17: RNAi: The Awkward Age
16: Things I Won't Work With: Ozonides
15: Keep It To Yourself
14: I'll Have the Lot
11: Alexander Would Have Understood
10: Cui Bono?
09: Gumming Up the Amyloid Works
08: Merck's State of Mind
07: Take it Off!
05: A Visit To Academia
03: Don't Ask; Just Trade
02: Let's See What the Sharks Think of These Steaks!
01: Now With The Great Taste of Fish

October 2004
31: Well, Sonny, That's Not How We Did It
30: Special Off-Topic Weekend Irrelevancy
29: Different or Not? You Tell Me.
27: Pharma Flock Begins Migration
26: It's All Local, All Right
25: Actually, It's Everything Else That's Off-Topic
24: A Spin of the Wheel
22: Hey, I Could Patent That. . .
20: Ping! Ping! Ping!
19: Cox-2 Confusion
19: Epidemic of Good Sense Spreading, Scientists Say
17: Preach It, Brother
14: Could I Have a Side Order of Risk With That?
14: Circular Mistakes
12: A Day in the Life: Dichloromethane and Peanut Butter
11: Public Utility, You Say?
11: Prices and Innovation
07: How Bad Are the Cox-2 Inhibitors, Anyway?
06: We Have Ways of Keeping You Safe
05: Proteins to the Rescue?
05: DNA to Drug?
03: More on Merck
02: Comment Problems

September 2004
30: A Day With All the Bark Left On It
29: Peter Rost, Oddity
28: Kicking the Dinosaur's Tail - Again
28: Rank and Yank?
23: Measure for Mismeasure
22: Rational Drug Design
20: Two Days Off (From This, Anyway)
20: Drug Development: The Current Odds
19: No Coming Attractions Here
16: The NIH in the Clinic
14: One More On Basic Research and the Clinic
13: A Real-World Can O' Worms
12: How Much Basic Research?
09: How It Really Works
08: Unburied
07: Angell's Book
02: The Last Word (For A While) On Me-Too Drugs
01: Around and About

August 2004
31: Me Too, Part Two
31: Clinical Trials And What to Do With Them
29: . . .It's a Wonder I Can Think At All
26: Things I Won't Work With: Polyazides
25: Will the Uncommon Work for the Common Good?
24: Living by the IP Sword
24: I'll Have the Price They're Having
19: Empty Shelves
18: Resistance to Resistance
17: Kinases and Their Komplications
16: Clay Lies Still, But Blood's A Rover
15: FullCell 1.0?
12: A Week in the Life
10: Memorial
10: Solid Citizens
09: Fast, Cheap, and Sometimes Even Good
05: The State of the State of the Art
04: Things I Won't Work With: A Nasty Condensed Gas
03: Silent Mutations and Noisy Ones
02: Research, The Right Way
01: Furry Judges, With Tails

July 2004
30: John Kerry on Drug Prices
29: Down in the Salt Mine
28: A Question For the Audience
28: How Long Can This Go On?
26: How Not to Do It: Sulfenyl Chlorides
25: Costs and Benefits, Risks and Rewards
22: Another Shot Across the Bow
20: Worries about Rimonabant?
19: Bungee Jumping with PPAR Drugs
18: Back for More
08: How Do You Know When to Stop?
06: Lighting Out for the Frontier
04: Happy Fourth of July
02: The Two Ends of the Stick
01: So What's Wrong With A Little Money Changing Hands?

June 2004
28: No Defense
27: Loose Lips
24: Summer Hours
23: It'll Cost You
21: Primum Non Nocere, Eh?
21: Le Dernier Cri
17: You'd Think It Was An Election Year or Something
16: The Dull Edge of Nanotech
15: The Journals Fight Back
14: Wipe Down
13: Dumpster Diving for Data?
11: The Agents Report Back
09: Your One-Stop Clinical Data Superstore?
08: Cue the Music
07: Vox Populi
06: As Goes ASCO. . .
03: Doublets, Triplets, Whateverlets
02: This Isn't the Kind of Office Action You're Thinking Of
02: Industry vs. Academia: The Mental Aspect

May 2004
31: How Not to Do It: Sodium
26: The Latest From the Fishing Hole
25: Down the Hatch
24: What Ails Us
23: Catalyst Catfishing
20: A Capacious Rat-Hole Indeed
19: All the Myriad Ways
19: The Dose Makes the Poison
17: Next on the Food Channel. . .
16: Owning the Road
14: The Last Word on Taste
12: Beyond the Teeth, Beyond the Pale
11: By Any Other Name
10: Why Own the Car, When You Can Own the Road?
09: Meetings and Their Discontents
06: A Fire, And Its Flames
05: Price Hydraulics
04: Deferred Gratification Is Better Than None At All
03: At My Desk, Playing 500-Card Stud
02: Odd Elements in Drugs: Silicon

April 2004
29: Yahoots
29: An Era Begins
28: Foaming Up Over the Edge
27: Bulking Up
26: Thou Hast It Now. . .
25: How Not to Do It - Hydrogen Balloons
23: Categories
22: The Vapor Trail I Referred To
21: Mutter, Mutter, Mutter
20: Stuart Schreiber on Stuart Schreiber
19: Odd Elements in Drugs
18: The March of Folly Leader Board
16: Welcome Back!
15: The March of Folly
14: Reality's Revenge
13: It's a Bacterial Planet, You Know
06: Osmium Tetroxide, Of All Things
05: Oblivious to One Skilled in the Art
04: Obvious to One Skilled in the Art
01: Differences Between Academia and Industry, Pt. 2

March 2004
31: No Better Than the Rest of Them
29: Play It Again
28: Thing I Won't Work WIth (2): Nickel Carbonyl
25: A Birthday Worth Noting
25: Tasty New Recipes for the Root of All Evil
23: Getting the Word Out, For Once
22: Quis custodiet ipsos custodes?
21: The Root of All Results?
18: Differences Between Industry and Academia, Pt. 1
17: Our Cheerful Buddy, The Cell Membrane
15: Pravachol vs. Lipitor Update
15: The Universe, Which Others Call the Library. . .
14: Mismatched Socks
11: Ignorance Was Bliss
10: A Mechanism for Thimerosal
09: Nuclear Fusion, Wordsworth, German Cooking. The Usual.
07: They Will Do Such Things. . .
04: Welding the Steering Wheel
03: Things I Won't Touch (1)
02: Catching Up

February 2004
29: More From the Me-Too Front
26: Putting A Price on Proving It
25: Ezetimibe, The Press, and More
24: The Beginning? It's Right Past the End. . .
23: One Of Us Is Hallucinating
22: Reimportation's Just the Beginning
19: One Of Us Is Hallucinating
19: All Fixed Up
18: How Drugs Die
16: The Old Days, Some Older Than Others
15: Drug Prices and Costs - From the Mail
15: Easterbrook Post Updated
12: More on Prices, High and Otherwise
12: The Cold Equations
11: The Contact Sport of Cost Accounting
09: I will do such things - What they are yet I know not. . .
08: Darn Those R&D Costs, Anyway
05: Sic Transit Gloria Mundi
04: Our Friend, the Carbon-Aluminum Bond
03: Ricin Redux
02: How to Be an Inventor
01: Ricin Redux
01: Deal Me In

January 2004
29: From Each According To Their Creativity, To Each According To Their Difficulty?
28: The Best Bad News He Ever Had
28: Not in My European Back Yard
26: Allons Pharmas de la Patrie!
25: A Little Ambiguity Would Be Welcome Right About Now
22: Dr. Lowe? I Have Your Hypothesis on Line Two
21: . . .Your Huddled Pharmas Yearning to Breath Free
20: Weinberg's "Golden Lessons"
19: There'd Better Not Be an Argon Receptor
18: All Bets Are Now Officially Off
15: And Now for Something Completely Different
14: The Pricing Weapon
13: Here and There
12: If This Doesn't Work, There's Only Reality To Fall Back On
11: A New Cancer Target - Maybe
08: A Request From Biology
07: Good Sense Wins a Round
07: Secretin

December 2003
07: Good News, Backing Slowly Through the Door?

November 2003
28: Waiting for the Metaphorical Phone to Ring

August 2003
03: Per Fits and Starts, Ad Astra

January 2003
12: Easy Parts and Hard Parts
09: Back in the Stacks
08: More Ricin
08: The Library of Babel
07: Ricin
06: And Another Thing. . .
06: Compare and Contrast
05: Ratio Rationalizations
02: The Rate of Autism

December 2002
30: Back on the Air
22: Clearance Sale
22: Thimerosal - A Chemical Point
22: Thimerosal - a Chemical Point
22: Clearance Sale
20: Trials of Trials
18: Hypertension and Marketing
17: Looking Back, Looking Forward
16: Attitude
12: A Rough Business
11: A Quick One While He's Away
10: Don't Wait - Patent Today!
09: Proteinocentrism
09: Sweet Maybe, But Trouble, Too
05: A Quick Tour Through the Mudhole
05: More on Autism (And Mercury)
05: More on Autism and Mercury
05: A Quick Tour Through the Mudhole
04: Neurotoxins
04: Neurotoxins
03: Doing Justice to Thimerosal, And the Story
03: Doing Justice to Thimerosal, and the Story
02: Europe, Again
01: Place Your Bets

November 2002
26: Unequivocal Good News
25: A Chemical Wish List
24: A New Form of Hype, uh, Life?
21: The Future and Its Friends
20: What I, um, Meant to, um, Say
19: Ah, Marketing
18: Multitasking
17: New! Improved! Now With Stickier Lumps!
14: Statins and Multiple Sclerosis
14: Left and Right, Revisited
12: Y'all Are Going to Think I'm Nuts, But. . .
11: Thalidomide in the Mirror
10: Mismeasure for Mismeasure
07: Measure for Measure
04: Generic Prilosec - the Sequel
04: The Good Old Days of Really Bad Teeth, Revisited
04: It'll Be a While
04: Pneumonia, of All Things
03: Cholesterol Lowering, One Way or Another

October 2002
31: And While We're On the Subject - Mercury?
31: More Faces in Even More Clouds
30: What Sort of Number Did You Have in Mind?
29: Et in Arcadia Ego
28: A Mystery Gas?
27: O Brave New Market, That Has Such Medicines In It
24: Of All Sad Words. . .
23: The Latest Mudfight
21: Structure-Inactivity Relationship Would Be More Like It
20: Faces In the Clouds
17: Not Even Funny
16: Cloning's Growing Pains
15: That Voodoo That We Do
14: Gene Therapy Decisions
13: Nobelity and Lesser Nobelity
11: Alzheimer's Vaccine Refuses to Die
10: Another Stuffed Shirt
09: Nobel Time!
09: The Bigger They Are
08: Genetic Optimism
07: Idle Hands
06: Bad News at a Bad Hour of the Night
03: Am I Blue?
02: Voluntary. . .For Now
01: Silver Tongues, Golden Hands?
01: Overpatenting?

September 2002
30: Where Credit's Due
29: A Rake's Progress
26: On the Money
25: Different Opinions About A Difference That Makes No Difference
24: The Wall Street Journal versus the FDA
22: Sleeping Dragons
19: More Fun With Patent Expirations
18: As Others See Us
15: Chemical Warfare, Part Five: The Real World
14: Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
13: Chemical Warfare, Part Three: How Nerve Agents Work
12: Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
12: Chemical Warfare, Part One: Introduction
09: Caveat Lector
08: Merck and Its Competition
05: You Don't Hear "Eureka" That Often
03: The Patent Expiration Fun Continues
02: A Last-Ditch Effort - Or Is It?

August 2002
29: How Not to Do It: Solvent Stills
28: Consequences of Aneuploidy
27: Aneuploidy, or What're A Few Chromosomes, More or Less?
26: Muddying the Water For Fun and Profit
25: Back For Some More
20: HER-1 And HER-2, Too
19: They All Get Real at Some Point
18: And I Still Have Some of Those Shirts
16: Here It Goes
16: Nature Stood Me Up
15: Great Moments in Legal Reasoning
14: Our Friend the Phosphate Group, Redux
13: Our Friend the Phosphate Group
11: Life of the Party
08: Better Them Than Me
04: Close to the Vest
04: Close To the Vest
01: Breathing and Aging

July 2002
30: The Ames Test and the Real World
29: The Ames Test
28: Our Buddies at the FDA
25: What to Do When the Rats Die on You
24: Experimental Update
24: And Always Keep Ahold of Nurse, For Fear of Finding Something Worse
23: Rats, For Fear of Worse
22: More on Drug Prices
21: You'll Only Get Answers
19: The Dismal Science of Drug Prices
18: Talk, Cheap and Otherwise
17: A Twisty Road
16: Marketing Ueber Alles
16: By Any Other Name
15: The Apatosaurus. The Spruce Goose. The Pyramids
15: The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
12: More Pfizer Explosion Details
11: New! Viruses So Potent, You'd Swear They Were Homemade!
10: Fighting City Hall
09: Maybe They Can Formulate It in Madelaines
02: Now, Where Was I?

June 2002
26: A Race to the Bottom
25: Blowups Happen
24: Another Shot
23: Stupidity, But Not the Dangerous Kind
18: Save Your Tears
16: A Strange Compound, In Strange Places
13: The Company You Keep
11: And All For a Little Money
06: Adam Smith Goes Pharmaceutical
04: A Clean Lab is A Happy Lab
03: When Natural Selection's Through With You - Part II
03: It's Not Pretty, But It Works

May 2002
31: In Case Anyone's Wondering
30: Innovation and Its Discontents
28: Back to Whatever It Is I Do
23: A Few Words
22: Did He Say What They Thought He Said?
22: Now Is the Peptide of Our Discontent
21: Hype and Glory
20: Hands Off
19: Not As Bad As It Looks
15: Eliminate the Middleman
14: After Natural Selection's Through With You
12: Back for More
06: Meanwhile, Back at the Chocolate Factory
06: Claritin and Clarinex
06: So What's A Worthwhile Problem, Anyway?
03: The Nuts and Bolts of a New Idea
02: Measure Twice, Cut Once
02: Anything Worth Doing. . .

April 2002
22: Fun While It Lasted
19: Colors May Fade
15: A Treadmill Pill?
12: A Less-Than-Subtle Plan
09: And Another Thing
08: F. Scott Fitzgerald Had Something to Say About This
07: Get Your Miracle Elixir
02: Nothing Like It in the World
01: Enzymes, Right and Wrong

March 2002
28: Not Like Law School
28: Cruel to Be Kind
24: What's a Project Manager to Do?
22: More Colors and Smells
20: If It Were Easy. . .
19: Mirror Stars
10: Separation Anxiety

February 2002
27: More Imclone, More Food for Thought
27: Who Dares, Wins?
26: A Certain Tension in the Air
26: New Drugs for HIV
25: All the Not-So-Myriad Ways
24: Toxicolottery
22: Cartesian Aging
20: Giordano Bruno
18: A Couple of Days Off
14: Modeling the Brain?
06: Imclone in Progress
05: Why Total Synthesis?
03: Climbing Mountains
01: Medicine Man